LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Aandelen Lijst・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

18.73 -4.15

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.56

Max

19.54

Belangrijke statistieken
By Trading Economics
Inkomsten	25M -43M
Verkoop	-3.6M 65M
EPS	-0.48
Winstmarge	-65.788
Werknemers	298
EBITDA	-16M -31M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+106.74% upside

Dividenden
By Dow Jones
Volgende Winsten	3 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-77M 1.8B
Vorige openingsprijs	22.88
Vorige sluitingsprijs	18.73

Syndax Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 jun 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 jun 2026, 23:38 UTC

Acquisities, Fusies, Overnames

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 jun 2026, 23:37 UTC

Marktinformatie

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 jun 2026, 23:01 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 23:01 UTC

Marktinformatie

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 jun 2026, 22:08 UTC

Acquisities, Fusies, Overnames

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Acquisities, Fusies, Overnames

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Acquisities, Fusies, Overnames

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 jun 2026, 21:55 UTC

Acquisities, Fusies, Overnames

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 jun 2026, 21:53 UTC

Marktinformatie

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 jun 2026, 21:22 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 jun 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

1 jun 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jun 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

1 jun 2026, 20:46 UTC

Acquisities, Fusies, Overnames

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 jun 2026, 20:22 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 jun 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 jun 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Declares $11 Special Div

1 jun 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 jun 2026, 19:40 UTC

Marktinformatie

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 jun 2026, 19:28 UTC

Marktinformatie

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 jun 2026, 19:01 UTC

Marktinformatie

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 jun 2026, 18:58 UTC

Marktinformatie

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 jun 2026, 18:54 UTC

Acquisities, Fusies, Overnames

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 jun 2026, 18:33 UTC

Marktinformatie

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 jun 2026, 18:32 UTC

Marktinformatie

Precious Metals Fall to Start June -- Market Talk

1 jun 2026, 18:00 UTC

Acquisities, Fusies, Overnames

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 jun 2026, 17:18 UTC

Marktinformatie

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 jun 2026, 17:18 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 17:10 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer Vergelijking

Prijswijziging

Syndax Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

106.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 40.5 USD 106.74%

Hoogste 57 USD

Laagste 29 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Syndax Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Syndax Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.